Suscribirse

Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response - 03/11/22

Doi : 10.1016/j.diii.2022.06.007 
Ahmed S. Abdelrahman a, , Mena E.Y. Ekladious a, Ethar M. Badran b, Sherihan S. Madkour a
a Radiology Department, Faculty of Medicine, Ain Shams University, 11591 Cairo, Egypt 
b Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, 11591 Cairo, Egypt 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Highlights

Liver imaging reporting and data system (LI-RADS) treatment response algorithm (LR-TR) v2018 has excellent diagnostic performance and reliability for the diagnosis of residual hepatocellular carcinoma after locoregional treatment.
LR-TR enhancement characteristics and final category show interobserver agreement of 0.815 and 0.795, respectively.
The LR-TR algorithm v2018 is recommended for reporting hepatocellular carcinoma treatment response after locoregional therapy.

El texto completo de este artículo está disponible en PDF.

Abstract

Purpose

The purpose of this study was to determine the reliability and interobserver agreement of the liver imaging reporting and data system (LI-RADS) treatment response algorithm (LR-TR) v2018 using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and the added value of diffusion-weighted imaging (DWI).

Materials and methods

A total of 54 patients who underwent DCE-MRI and DWI after locoregional treatment of 81 hepatocellular carcinoma (HCC) lesions from September 2020 to July 2021 were included. There were 47 men and 7 women, with a mean age of 63.9 ± 9.2 (SD) years (age range: 23–77 years). Locoregional treatments included transarterial chemoembolization (TACE) (53/81; 65.4%), radiofrequency ablation (RFA) (25/81; 30.9%) and microwave ablation (MWA) (3/81; 3.7%). Two independent radiologists retrospectively evaluated DCE-MRI examinations obtained after locoregional treatment using LR-TR, and then three months later both radiologists reevaluated DCE-MRI examinations with DWI. Interobserver agreement was assessed using intraclass correlation coefficient (ICC) and Kappa test. Diagnostic performances were evaluated in term of sensitivity, specificity, and area under ROC curve (AUC) using a composite standard of reference that included results of histopathological examinations and follow-up findings.

Results

Using DCE-MRI alone, observer 1 had 83.9% sensitivity (26/31; 95% confidence interval [CI]: 66–95%), 88% specificity (44/50; 95% CI: 76–95%) and 86.4% accuracy (70/81; 95%CI: 77–93%), and observer 2 had 71% sensitivity (22/31; 95% CI: 52–86%), 92% specificity (46/50; 95% CI: 81–98%) and 83.9% accuracy (68/81; 95% CI: 74–91%). For the diagnosis of viable tumors using DCE-MRI with DWI, observer 1 and observer 2 had 87.1% (27/31; 95% CI: 70–96%) and 74.2% (23/31; 95% CI: 55–88%) sensitivity, respectively. The diagnostic performance of DCE-MRI with DWI yielded an AUC (0.875; 95% CI: 0.789–0.962) not different from that of DCE-MRI without DWI (0.859; 95% CI: 0.768–0.951) (P = 0.317). Interobserver agreement for arterial phase hyperenhancement, washout, enhancement similar to pretreatment and DWI findings in all treated HCCs was almost perfect (kappa = 0.815, 0.837, 0.826 and 0.81 respectively). Agreement between observers for LR-TR category was substantial (kappa = 0.795; 95% CI: 0.665–0.924). Interobserver agreement for size of viable HCC was excellent (ICC = 0.938; 95% CI: 0.904–0.960).

Conclusion

LR-TR using DCE-MRI alone or DCE-MRI with DWI are both accurate for detecting viable HCC lesions after locoregional treatment, with no differences in diagnostic performance and excellent interobserver agreement.

El texto completo de este artículo está disponible en PDF.

Keywords : Chemoembolization, Hepatocellular carcinoma, LI-RADS treatment response (LR-TR), Magnetic resonance imaging, Radiofrequency ablation

List of abbreviations : ADC, APHE, CBCT, CI, CT, cTACE, DCE, DWI, FOV, HCC, HCV, ICC, LI-RADS, LR-TR, mRECIST, MRI, MWA, NPV, PPV, RECIST, RFA, SD, TACE, TE, TR


Esquema


© 2022  Société française de radiologie. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 103 - N° 11

P. 524-534 - novembre 2022 Regresar al número
Artículo precedente Artículo precedente
  • Single-session transarterial chemoembolization combined with percutaneous thermal ablation in liver metastases 3 cm or larger
  • Adrian Kobe, Lambros Tselikas, Frédéric Deschamps, Charles Roux, Alexandre Delpla, Eloi Varin, Antoine Hakime, Thierry De Baère
| Artículo siguiente Artículo siguiente
  • 3D convolutional neural network model from contrast-enhanced CT to predict spread through air spaces in non-small cell lung cancer
  • Junli Tao, Changyu Liang, Ke Yin, Jiayang Fang, Bohui Chen, Zhenyu Wang, Xiaosong Lan, Jiuquan Zhang

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.